

3 July 2015

Company Announcements Office
Australian Securities Exchange
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

NOTICE UNDER SECTION 708A OF THE CORPORATIONS ACT

This notice is given by Sun Biomedical Limited pursuant to section 708A(5)(e) of the Corporations Act (**ACT**).

The Company has issued:

- 100,000,000 fully paid ordinary shares (**Shares**) at an issue price of \$0.01 per share, pursuant to a share placement announced on 13 May 2015 and completed on 3 July 2015;
- the following securities as consideration for the Company's acquisition of 100% of the issued shares in Dimerix Bioscience Limited (**Dimerix**) (the **Acquisition**) on completion of the Acquisition (**Completion**) on 3 July 2015:
 - 750,000,041 Shares;
 - 75,000,040 Class A Performance Shares (convertible into 75,000,040 Shares upon receipt by the Company or Dimerix of a notice of allowance from the United States Patent and Trademark Office in relation to the US patent application number 13/979,127 (or any divisional or continuation thereof) within 24 months of Completion);
 - 75,000,040 Class B Performance Shares (convertible into 75,000,040 Shares upon the Company's board of directors making an investment decision to proceed to file an application to the US Food and Drug Administration for a pre-Investigational New Drug ("pre-IND") meeting to progress development of DMX200 following the receipt of data generated under the current clinical trial for chronic kidney disease supporting further progression of the technology within 48 months of Completion); and
 - 75,000,040 Class C Performance Shares (convertible into 75,000,040 Shares upon receipt of ethics approval allowing commencement of a second clinical trial derived from the Dimerix platform and in relation to an indication that is not covered under the existing Austin Human Research Ethics Committee approval within 48 months of Completion);
- 60,000,000 options over unissued Shares (exercisable at \$0.01 per option on or before 30 June 2017) on 3 July 2015; and
- 30,851,594 options over unissued Shares (exercisable at \$0.02 per option on or before 30 June 2017) on 3 July 2015,


(together, the **Securities**)

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Company issued the Securities without disclosure to investors under part 6D.2 of the Act;
2. as at the date of this notice the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company and section 674 of the Act; and

3. as at the date of this notice there is no information:
 - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
 - b. that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - ii. the rights and liabilities attaching to the Securities.

Yours faithfully



Peter Webse
Company Secretary